BMS picks up Novo Nordisk's unwanted anti-inflammatory program
This article was originally published in Scrip
Novo Nordisk, no longer interested in the autoimmune space, is making moves to focus almost entirely on its strength in diabetes by divesting assets to Bristol-Myers Squibb. The Danish pharma found a home for its early autoimmune development program with the US pharma.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.